For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for CVS Health Corporation (CVS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -43 (−100…+100 Quality+Value blend) · Quality -34 · Value -51 · Sentiment -26 (timing only, not weighted) · Composite fair value $110.27 vs $99.12 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
CVS Health Corporation
CVS NYSECVS Health Corporation is a leading health solutions company that provides comprehensive healthcare services across multiple segments. It operates through Health Care Benefits, offering health insurance and benefits to millions; Health Services, which includes pharmacy benefit management solutions, medical clinics, virtual care, and in-home services; and Pharmacy and Consumer Wellness, encompassing retail pharmacies and consumer health products. These segments enable CVS Health Corporation to deliver integrated care, from prescription management and drug dispensing to primary care and wellness offerings. The company serves individuals, employers, health plans, and government programs, playing a pivotal role in the U.S. healthcare ecosystem by bridging retail pharmacy, insurance, and clinical services. Founded in 1963 and headquartered in Woonsocket, Rhode Island, CVS Health Corporation stands as a key player in retail trade and healthcare services, focusing on accessible and coordinated health solutions in today's market.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 1.39
Total Equity: $75.38B
Shares: 1,271,000,000
Total Debt: $0.00
Cash: $8.45B
EBITDA: $9.27B
Total Debt: $0.00
Cash: $8.45B
Revenue: $402.07B
Revenue: $402.07B
Revenue: $402.07B
Total Equity: $75.38B
Tax Rate: 19.1%
Equity: $75.38B
Total Debt: $0.00
Cash: $8.45B
Current Liabilities: $88.69B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $75.38B
Shares: 1,271,000,000
Shares: 1,271,000,000
CapEx: -$2.83B
Shares: 1,271,000,000
Stock Price: $104.42
Net Income: $1.77B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 1:01am (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Cost of Revenue | $175.8B | $196.9B | $217.1B | $206.3B | $221.2B |
| Gross Profit | $116.3B | $125.6B | $140.7B | $166.5B | $180.9B |
| Operating Expenses | $103.1B | $117.8B | $126.9B | $158.0B | $176.2B |
| Operating Income | $13.2B | $7.7B | $13.7B | $8.5B | $4.7B |
| Net Income | $7.9B | $4.1B | $8.3B | $4.6B | $1.8B |
| EBITDA | $17.7B | $12.0B | $18.1B | $13.1B | $9.3B |
| EPS | $6.00 | $3.16 | $6.49 | $3.67 | $1.40 |
| EPS (Diluted) | $5.95 | $3.14 | $6.47 | $3.66 | $1.39 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:36am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9.4B | $12.9B | $8.2B | $8.6B | $8.5B |
| Total Current Assets | $60.0B | $65.7B | $67.9B | $68.6B | $74.7B |
| Total Assets | $233.0B | $228.3B | $249.7B | $253.2B | $253.5B |
| Current Liabilities | $67.8B | $69.7B | $79.2B | $84.6B | $88.7B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $157.6B | $157.0B | $173.1B | $177.5B | $178.2B |
| Total Equity | $75.4B | $71.3B | $76.6B | $75.7B | $75.4B |
| Retained Earnings | $54.9B | $56.1B | $61.6B | $62.8B | $61.2B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 1:01am (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $18.3B | $16.2B | $13.4B | $9.1B | $10.6B |
| Capital Expenditure | -$2.5B | -$2.7B | -$3.0B | -$2.8B | -$2.8B |
| Free Cash Flow | $15.7B | $13.5B | $10.4B | $6.3B | $7.8B |
| Acquisitions (net) | -$146.0M | -$139.0M | -$16.6B | -$95.0M | -$436.0M |
| Net Debt Issued / (Repaid) | -$9.3B | -$4.2B | $7.7B | $3.1B | $340.0M |
| Dividends Paid | -$2.6B | -$2.9B | -$3.1B | -$3.4B | -$3.4B |
| Stock Buybacks | $0 | -$3.5B | -$2.0B | -$3.0B | $0 |
| Net Change in Cash | $1.6B | $614.0M | -$4.8B | $359.0M | -$172.0M |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 1:01am (24d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +10.4% | +10.9% | +4.2% | +7.8% |
| Gross Profit Growth | +8.0% | +12.0% | +18.4% | +8.6% |
| Operating Income Growth | -41.3% | +77.4% | -38.0% | -45.3% |
| Net Income Growth | -47.5% | +101.1% | -44.7% | -61.7% |
| EBITDA Growth | -32.3% | +51.0% | -27.6% | -29.3% |
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:36am (18d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-23 | $0.67 | — | — | — |
| 2026-04-23 | $0.67 | — | — | — |
| 2026-01-22 | $0.67 | — | — | — |
| 2025-10-23 | $0.67 | — | — | — |
| 2025-07-22 | $0.67 | — | — | — |
| 2025-04-22 | $0.67 | — | — | — |
| 2025-01-23 | $0.67 | — | — | — |
| 2024-10-21 | $0.67 | — | — | — |
| 2024-07-22 | $0.67 | — | — | — |
| 2024-04-19 | $0.67 | — | — | — |
| 2024-01-19 | $0.67 | — | — | — |
| 2023-10-19 | $0.61 | — | — | — |
| 2023-07-20 | $0.61 | — | — | — |
| 2023-04-20 | $0.61 | — | — | — |
| 2023-01-19 | $0.61 | — | — | — |
| 2022-10-20 | $0.55 | — | — | — |
| 2022-07-21 | $0.55 | — | — | — |
| 2022-04-21 | $0.55 | — | — | — |
| 2022-01-20 | $0.55 | — | — | — |
| 2021-10-21 | $0.50 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:47Recovery pays +363%; another quarter like the worst recent one costs 67%. Ratio 5.4:1.
| Case | Growth | Margin | Fair value | vs price ($99.12) |
|---|---|---|---|---|
| Bull — recovery | +10% | 9.2% | $458.84 | +363% |
| Base — stabilizes | +6% | 8.0% | $358.96 | +262% |
| Bear — keeps slipping | +3% | 6.8% | $274.11 | +177% |
| Stress — last quarter repeats | +8% | 0.6% | $32.65 | -67% |
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a coherent but ugly story that the "high-growth profitable" archetype label completely mislabels. Revenue grew from $292B (2021) to $402B (2025) — a 6% CAGR that's respectable for a $130B market cap — but operating income collapsed from $13.19B to $4.66B over that same window, and net income went from $7.91B to $1.77B. That's not growth; that's a business scaling volume while destroying unit economics. Operating margin is 116 bps, net margin 44 bps, and ROE 2.35% against a book of $75B. The Q3 2025 -$3.98B loss (likely Medicare Advantage-related reserve builds and/or goodwill flushes) suggests the earnings base is still being restated downward. The rule-based classifier is simply wrong here — CVS is a low-margin conglomerate under structural stress, not a high-growth compounder.
That said, the balance sheet line reporting "$0 total debt" is almost certainly a data error — CVS carried roughly $75–80B of long-term debt post-Aetna and Signify/Oak Street deals; there's no plausible universe where they've retired it while FCF is $7.8B and they're paying a 2.76% dividend with a 192% payout ratio. EV/EBITDA of 12.3x with EV/revenue of 0.28x is more believable and implies the debt is in the enterprise value calc even if the balance sheet field is null. This matters because the bull case rests on FCF ($10.6B operating, $7.8B free) being real and durable — at $133B market cap that's a ~5.9% FCF yield, which is defensible if margins stabilize. But the payout ratio above 190% means the dividend is being funded from FCF, not earnings, and any further deterioration puts the $2.88/share dividend in play. Insider activity reinforces the caution: ~1.77M shares sold across May 20–21, 2026 with zero open-market buys. That's not routine vesting churn; that's conviction selling into strength.
I largely agree with the Market Forces "avoid" call and the synthesis fair value near $79, and I dissent from the mislabeled classification. Where I'd push back on the bears: the PBM/Caremark and Aetna franchises generate real, sticky cash flow, and at 0.30x sales CVS is priced for continued erosion — any margin normalization toward even 1.5% net (half of historical) would generate ~$6B in earnings, or ~$4.70 EPS, dropping the P/E to ~22x on a still-depressed base. The narrative layer's 25.6% premium-to-DCF framing seems roughly right directionally but I'd argue the premium is really an option value on MA reserves normalizing in 2026–2027 as CVS reprices plans and exits unprofitable counties. That's a real catalyst, not just narrative sugar. The contrarian long case: buy the trough MA cycle, get paid 2.76% to wait, and re-rate to $130+ if 2027 earnings recover to $7–8/share. That's not a crazy setup — it's how you made money in HUM and UNH historically after cycle troughs.
But the contrarian case still loses on evidence weight. Three things kill it: (1) the earnings trajectory is still deteriorating — Q3 2025 was a $4B loss and Q4/Q1 print $2.94B each, which is not yet a clean inflection; (2) insider selling of ~1.8M shares in two days signals management doesn't see the trough here; (3) the payout ratio math means either the dividend gets cut (removing yield support) or FCF must inflect fast. Meanwhile PBM reform risk (Lina Khan's FTC report, bipartisan legislation) and Amazon Pharmacy are real, non-narrative overhangs. At $104, you're paying 69x trailing earnings and ~14x a hoped-for normalized $7.50 EPS that's still two years out with execution risk. The synthesis's $79 fair value looks about right; I'd put my own fair value at $80–90 depending on how you credit MA normalization. Current $104 is 15–25% too high for the risk. I'd wait for either (a) a dividend cut that clears the air, (b) a clean two quarters of MA MLR improvement, or (c) sub-$85 to establish a starter position. The models are directionally correct that this is fully priced to overvalued; the classification engine is embarrassingly wrong to call it high-growth profitable.
GPT Reading
What stands out is that CVS is not a growth stock in any economically meaningful sense right now; it is a massive revenue machine whose profit pool has been squeezed to a sliver. Revenue climbed from $292.1B in 2021 to $402.1B in 2025, a healthy 8% annualized pace for a company this large, and the latest quarter at $100.4B was up about 6% from $94.6B a year earlier. But that growth has not translated into earnings power. Net income has fallen from $7.9B in 2021 and $8.3B in 2023 to just $1.8B in 2025, with operating income down from $13.7B in 2023 to $4.7B in 2025. On $402B of sales, CVS produced a 1.2% operating margin and a 0.4% net margin last year. That is the core fact. The stock is being asked to trade on normalized earnings, not reported earnings, because reported earnings make the valuation look stretched at 69x P/E.
The quarterly pattern does suggest 2025 may have been a trough rather than a new base, but only partly. After a weak mid-2024 to late-2025 stretch that included a near-breakeven quarter in 3Q24 and a large loss in 3Q25 of -$4.0B, the last two quarters look better: $2.94B of net income in both 4Q25 and 1Q26, with margins back to 2.8%-2.9%. If those levels were sustainable, annualized earnings power would be closer to $11B-$12B, which would make today’s $133B market cap much more reasonable. That is the entire bull case embedded in the current price: not that CVS is cheap on trailing numbers, but that the ugly 2025 print materially understates earning power. Cash flow supports some of that argument. Operating cash flow of $10.6B and free cash flow of $7.8B are far healthier than the net income line, and the valuation on those cash flows is not demanding for a scaled healthcare infrastructure asset. A roughly 17x FCF multiple on depressed margins is not a distressed multiple.
Still, I think the market is giving CVS too much credit too soon. The structural trend is ugly: revenue up 35% since 2021, net income down 78%, and free cash flow also shrinking over time. Gross margin has improved in dollars, but operating leverage has gone the wrong way, implying that the company’s scale is not translating into bargaining power or cost absorption. The business mix may be inherently lower margin, but then the stock should not get the benefit of a “temporary dip” narrative so easily. The payout ratio near 192% of earnings also tells you the dividend is currently being funded by cash generation rather than income statement strength; that can continue, but it is not a marker of balance-sheet-free comfort. The balance sheet data show zero debt, which is almost certainly an artifact of the dataset rather than economic reality, so I would not let that flatter the credit picture. And the insider tape is poor: multiple sizeable sales in May 2026 totaling well over 1.7 million shares is not dispositive, but it is inconsistent with a management team signaling obvious undervaluation.
The best argument against my skepticism is simple: CVS may have already done the hard reset. If 3Q25 contained unusual charges and if 4Q25 plus 1Q26 are closer to normalized profitability, then trailing annual metrics are badly misleading. On that view, the right lens is not 69x earnings on $1.77B of net income, but maybe 12x-14x a normalized $9B-$11B earnings stream for a company still growing revenue high single digits, generating $8B of free cash flow, and trading at just 0.3x sales and 1.6x book. That would make the current price not expensive at all. I weigh that argument less heavily because I do not yet see enough evidence that margin restoration is durable across a full year rather than a couple of better quarters after a washout period. CVS has to prove that 2.5%+ net margins are recurring, not episodic.
What would change my mind is straightforward. If the next two quarters hold revenue around or above $100B while keeping net income above $2.5B each quarter, that would establish a run-rate where annual earnings power is back near $10B and the stock would look fine, even modestly cheap, at $104. I would also want to see full-year operating income recover clearly above $8B, back toward 2024 levels, while free cash flow remains above $8B. Conversely, another quarter with sub-1.5% net margin, or any sign that the 3Q25 loss was not an isolated event but part of persistent reimbursement or utilization pressure, would make even $104 look rich. For now, the numbers say this is a turnaround being priced as if the turnaround is already substantially won.
Grok Reading
The numbers tell a story of a volume machine that has lost control of its unit economics. CVS grew revenue from $372.8B in 2024 to $402.1B in 2025 and is still printing roughly $95–105B a quarter, yet operating income collapsed from $13.7B in 2023 to $8.5B in 2024 to $4.7B in 2025, and net income fell to $1.77B—a 0.44% net margin and a 69x trailing P/E. That is not cyclical noise; it is multi-year structural compression. Gross margin held near 45%, so the bleed is downstream—medical cost pressure in the Aetna book, pharmacy reimbursement squeeze, and integration drag. Free cash flow of $7.81B on $10.6B operating cash flow remains the one bright spot and still covers the roughly $3.7B dividend, but FCF is itself declining at a 13% CAGR and the 192% earnings payout ratio advertises that the dividend is being defended by cash conversion, not by earnings power. Returns on capital are abysmal: ROE 2.4%, ROIC 5.6%, ROA 0.7%. The balance-sheet print of zero debt is almost certainly incomplete or mis-tagged for a company of this scale, but even taken at face value the equity base of $75B is earning almost nothing. Recent quarters show $2.94B of net income in both Q4 2025 and Q1 2026 after a -$4.0B wipeout in Q3 2025; that two-quarter run-rate is the only quantitative hint of stabilization, and the market is clearly capitalizing some version of it. At $104 the stock sits at 0.30x sales and 12.3x EV/EBITDA—optically cheap on the top line, expensive on the bottom line that actually matters.
The prior models’ “high-growth profitable” archetype is simply wrong given a -54% earnings CAGR, and the valuation synthesis fair-value band around $79–94 looks directionally correct against current cash earnings. Heavy insider sales in May 2026 (multiple blocks of 150k–800k shares) and a decelerating quarterly revenue trend add weight to the bear case rather than the platform-monopoly narrative. The integrated Aetna–PBM–retail story is still the only justification for paying a mid-teens free-cash-flow multiple and a 25%+ premium to DCF, yet five years of post-deal evidence show value destruction, not capture.
The strongest counter-argument is that $1.77B is a trough distorted by the Q3 charge, and that two consecutive $2.94B quarters already imply a $10–12B earnings run-rate. On that basis the forward P/E compresses to roughly 11–13x, the 2.8% yield becomes comfortably covered, and a re-rating toward historical 2%+ net margins would make $104 look like a gift. Revenue confidence is still labeled “good,” FCF quality is strong, and a zero (or low) leverage structure would give management time to execute. If medical-cost trends normalize and the PBM book stabilizes, the market’s willingness to look through 2025 is rational, not reckless.
I would flip if the next two reported quarters sustain net income above $2.5B with operating margin expanding back through 2%, or if management guides 2026 NI above $8B with visible medical-benefit-ratio improvement; conversely, another impairment cycle or sub-1% operating margins would confirm the structural-bear reading and push fair value toward the low $70s.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
CVS scales at $402B revenue (2025) with gross margin actually expanding from 39.8% (2021) to 45.0% (2025), and it converts to real cash: $7.81B FCF, OCF/NI of 3.16x, accruals -3.4% of assets, Beneish M -2.58 — mechanically clean earnings. Balance sheet shows $10.6B liquid cash with net cash positive, and diluted shares shrunk from 1.33B to 1.27B (-1.1% CAGR) with buybacks running 329% of SBC. Those are hallmarks of a mature, self-funding operator.
Verify before trusting this (6)
- Medical benefit ratio at Aetna and 2025 guidance for MBR trajectory
- Pharmacy Services (Caremark) segment margin trend and PBM contract retention
- Total debt load and maturity schedule post Signify/Oak Street acquisitions
- Goodwill/intangibles balance and any impairment testing disclosures given profit collapse
- Whether Larry Robbins sales were 10b5-1 scheduled and his remaining stake
- Working capital and rebate receivable dynamics behind FCF decline from $15.75B to $7.81B
The composite fair value is $94 and the signal-adjusted FV is $79, both below the $99.12 price — implying roughly -20% downside on the synthesis. The DCF at $140 looks like the runaway input (it extrapolates cash generation without penalizing the operating-margin collapse the quality lens flagged), while the EPV floor of $75 and the anchored PE of $29 bracket a much more sober deserved value. Averaging the sober inputs lands near $50-75, right where the signal-adjusted FV sits. Earnings quality is high, so no extra haircut is warranted, but the business-quality lens (score -34, operating margin down ~75%, net income -78% from 2021) argues against paying a premium multiple. What is priced in at $99: that the Aetna-integrated platform thesis works, medical loss ratios normalize, and earnings power rebuilds toward prior peaks. That is the bull case, not the base case. Nothing here screams overvalued in a dangerous way — this is a mature cash generator, not a bubble — but there is no discount either. You are paying full freight for a business whose P&L is deteriorating, betting the integration story turns.
Verify before trusting this (4)
- Forward MLR guidance and whether Q4/2025 shows medical cost stabilization
- Aetna segment operating margin trajectory vs prior peak
- Free cash flow conversion holding up despite net income decline
- Any impairment or restructuring charges distorting the anchored-PE input
The macro tape is mildly risk-on and CVS is a low-beta (0.6) healthcare name, so the market regime barely touches this stock either way. What matters is the stock-specific narrative pressure, and right now that pressure is negative despite an objectively strong quarter. CVS printed a 40% adjusted EPS surge, raised full-year guidance, and still fell about 5.8% on the day because the 2027 outlook underwhelmed. That is a classic sign of a story running ahead of delivery: the integrated-care bull case demands accelerating earnings recovery, and management gave investors a slower ramp. When a beat-and-raise is sold, sentiment is doing the talking, not fundamentals. Offsets are real but modest. Healthcare was broadly bid late Wednesday, CVS made a headline DTC weight-loss partnership with Lilly (associating it with the hottest drug narrative in the market), and it was cited among Q2 medical-stock standouts. Analyst tone on the print was reportedly positive. But the price action is the tell: a raised outlook could not hold a bid, and the platform-monopoly narrative has only moderate intensity and low cult coefficient, so there is no true-believer base to defend dips. Net: a persistent, ordinary headwind, not a crisis.
Verify before trusting this (5)
- Whether sell-side price targets get revised down on the 2027 guide or hold on the 2026 raise
- Post-earnings drift over the next 5-10 sessions - does the gap fill or stay open
- Any follow-through on the Lilly DTC partnership (script volumes, expansion of the drug lineup)
- PBM reform headlines or pharmacy reimbursement news that could reinforce the bear narrative
- Whether healthcare sector rotation persists or fades if risk-on broadens back into tech
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 6, 2026, CVS was $99.12. We expect it to be $103.50 by Feb 2027, and we consider it great value under $78.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 6, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.